GSA Capital Partners LLP purchased a new stake in Sight Sciences, Inc. (NASDAQ:SGHT – Free Report) during the second quarter, according to its most recent filing with the SEC. The fund purchased 167,564 shares of the company’s stock, valued at approximately $908,000.
Several other hedge funds have also bought and sold shares of SGHT. Alliancebernstein L.P. boosted its holdings in shares of Sight Sciences by 5.5% during the 3rd quarter. Alliancebernstein L.P. now owns 34,380 shares of the company’s stock valued at $118,000 after purchasing an additional 1,800 shares during the last quarter. Deutsche Bank AG increased its holdings in shares of Sight Sciences by 9.8% in the fourth quarter. Deutsche Bank AG now owns 27,355 shares of the company’s stock worth $217,000 after purchasing an additional 2,439 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Sight Sciences by 32.7% in the second quarter. Tower Research Capital LLC TRC now owns 11,665 shares of the company’s stock worth $48,000 after purchasing an additional 2,875 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Sight Sciences by 1.0% in the third quarter. Dimensional Fund Advisors LP now owns 303,634 shares of the company’s stock worth $1,045,000 after buying an additional 3,051 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its position in shares of Sight Sciences by 99.8% in the third quarter. BNP Paribas Financial Markets now owns 7,579 shares of the company’s stock worth $26,000 after buying an additional 3,785 shares in the last quarter. Hedge funds and other institutional investors own 55.51% of the company’s stock.
Analyst Upgrades and Downgrades
Several research firms have weighed in on SGHT. Wall Street Zen upgraded Sight Sciences from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Citigroup reaffirmed a “neutral” rating on shares of Sight Sciences in a report on Thursday, August 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sight Sciences in a research report on Friday, August 7th. Finally, UBS Group raised their target price on shares of Sight Sciences from $7.00 to $8.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Five research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $7.88.
Sight Sciences Trading Down 0.2%
Shares of SGHT opened at $8.22 on Wednesday. Sight Sciences, Inc. has a twelve month low of $3.19 and a twelve month high of $9.24. The company has a market cap of $452.84 million, a P/E ratio of -14.68 and a beta of 2.38. The company has a current ratio of 4.95, a quick ratio of 4.67 and a debt-to-equity ratio of 0.58. The company’s fifty day simple moving average is $5.73 and its 200-day simple moving average is $5.00.
Sight Sciences (NASDAQ:SGHT – Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.10. Sight Sciences had a negative net margin of 35.69% and a negative return on equity of 43.39%. The firm had revenue of $23.39 million during the quarter, compared to analyst estimates of $21.72 million. As a group, analysts expect that Sight Sciences, Inc. will post -0.56 EPS for the current year.
Insider Activity
In other news, CEO Paul Badawi sold 28,684 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $5.42, for a total transaction of $155,467.28. Following the transaction, the chief executive officer owned 6,122,472 shares of the company’s stock, valued at approximately $33,183,798.24. This represents a 0.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CTO David Badawi sold 7,418 shares of the stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $5.51, for a total value of $40,873.18. Following the completion of the sale, the chief technology officer owned 1,982,872 shares in the company, valued at approximately $10,925,624.72. The trade was a 0.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 58,566 shares of company stock worth $318,827 in the last ninety days. 30.40% of the stock is currently owned by company insiders.
Sight Sciences Company Profile
Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.
Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.
Featured Articles
- Five stocks we like better than Sight Sciences
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Want to see what other hedge funds are holding SGHT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sight Sciences, Inc. (NASDAQ:SGHT – Free Report).
Receive News & Ratings for Sight Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sight Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
